{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cerebral+Small+Vessel+Diseases&page=5",
    "query": {
      "condition": "Cerebral Small Vessel Diseases",
      "page": 5
    },
    "page_size": 10
  },
  "pagination": {
    "page": 5,
    "page_size": 10,
    "total_count": 200,
    "total_pages": 20,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cerebral+Small+Vessel+Diseases&page=6&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Cerebral+Small+Vessel+Diseases&page=4&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-10-21T18:41:18.127Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01458119",
      "title": "Open-Label Phase 3 Long-Term Safety Study of Migalastat",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "migalastat hydrochloride",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Amicus Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "16 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "16 Years and older"
      },
      "enrollment_count": 85,
      "start_date": "2011-10-14",
      "completion_date": "2016-02-17",
      "has_results": true,
      "last_update_posted_date": "2018-10-02",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 11,
      "location_summary": "Atlanta, Georgia • Chicago, Illinois • Kansas City, Kansas + 8 more",
      "locations": [
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Kansas City",
          "state": "Kansas"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Grand Rapids",
          "state": "Michigan"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01458119"
    },
    {
      "nct_id": "NCT00987389",
      "title": "Plasma Exchange and Glucocorticoids for Treatment of Anti-Neutrophil Cytoplasm Antibody (ANCA) - Associated Vasculitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Granulomatosis With Polyangiitis (Wegener's) (GPA)",
        "Microscopic Polyangiitis (MPA)"
      ],
      "interventions": [
        {
          "name": "Plasma Exchange",
          "type": "PROCEDURE"
        },
        {
          "name": "No Plasma Exchange",
          "type": "OTHER"
        },
        {
          "name": "Glucocorticoids [Standard Dose]",
          "type": "DRUG"
        },
        {
          "name": "Glucocorticoids [Reduced Dose]",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "PROCEDURE",
        "OTHER",
        "DRUG"
      ],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "15 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "15 Years and older"
      },
      "enrollment_count": 704,
      "start_date": "2010-05",
      "completion_date": "2017-08",
      "has_results": true,
      "last_update_posted_date": "2020-05-26",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 9,
      "location_summary": "Los Angeles, California • Boston, Massachusetts • Rochester, Minnesota + 6 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Rochester",
          "state": "Minnesota"
        },
        {
          "city": "St Louis",
          "state": "Missouri"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00987389"
    },
    {
      "nct_id": "NCT04753970",
      "title": "Retina is a Marker for Cerebrovascular Heath",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Cerebral Small Vessel Diseases",
        "Cerebral Autosomal Dominant Arteriopathy With Subcortical Infarcts and Leukoencephalopathy",
        "Cerebral Microbleeding",
        "Sporadic White Matter Disease"
      ],
      "interventions": [
        {
          "name": "Cilostazol",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": true,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 100,
      "start_date": "2021-02-09",
      "completion_date": "2030-06",
      "has_results": false,
      "last_update_posted_date": "2026-08-03",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 1,
      "location_summary": "Jacksonville, Florida",
      "locations": [
        {
          "city": "Jacksonville",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04753970"
    },
    {
      "nct_id": "NCT00405860",
      "title": "CellCept in p-ANCA Vasculitis",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "MPO-ANCA Vasculitis",
        "Microscopic Polyangiitis"
      ],
      "interventions": [
        {
          "name": "CellCept (mycophenolate mofetil)",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Mayo Clinic",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2002-12",
      "completion_date": "2008-07",
      "has_results": false,
      "last_update_posted_date": "2011-03-23",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 1,
      "location_summary": "Rochester, Minnesota",
      "locations": [
        {
          "city": "Rochester",
          "state": "Minnesota"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00405860"
    },
    {
      "nct_id": "NCT02967068",
      "title": "VCRC Tissue Repository",
      "overall_status": "RECRUITING",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Aortitis",
        "Cutaneous Vasculitis",
        "Eosinophilic Granulomatosis With Polyangiitis",
        "Giant Cell Arteritis",
        "Granulomatosis With Polyangiitis (Wegener's)",
        "Henoch-Schonlein Purpura",
        "IgA Vasculitis",
        "Microscopic Polyangiitis",
        "Polyarteritis Nodosa",
        "Takayasu Arteritis",
        "Churg-Strauss Syndrome"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Pennsylvania",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "ALL",
        "summary": "Not listed"
      },
      "enrollment_count": 1000,
      "start_date": "2016-11",
      "completion_date": "2028-12",
      "has_results": false,
      "last_update_posted_date": "2026-01-22",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 6,
      "location_summary": "Boston, Massachusetts • Cleveland, Ohio • Philadelphia, Pennsylvania + 2 more",
      "locations": [
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Boston",
          "state": "Massachusetts"
        },
        {
          "city": "Cleveland",
          "state": "Ohio"
        },
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        },
        {
          "city": "Pittsburgh",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02967068"
    },
    {
      "nct_id": "NCT06051448",
      "title": "Promoting Resilience in Stress Management (PRISM) and Clinical-focused Narrative (CFN) Pilot in Adults With Primary Mitochondrial Disease (PMD).",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mitochondrial Diseases",
        "Mitochondrial Myopathies",
        "Mitochondrial Encephalomyopathies",
        "MELAS",
        "MERRF"
      ],
      "interventions": [
        {
          "name": "Promoting Resilience in Stress Management (PRISM)",
          "type": "BEHAVIORAL"
        },
        {
          "name": "Clinical-focused narrative (CFN)",
          "type": "BEHAVIORAL"
        }
      ],
      "intervention_types": [
        "BEHAVIORAL"
      ],
      "sponsor": "Children's Hospital of Philadelphia",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 16,
      "start_date": "2023-09-22",
      "completion_date": "2024-02-28",
      "has_results": false,
      "last_update_posted_date": "2024-11-29",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 1,
      "location_summary": "Philadelphia, Pennsylvania",
      "locations": [
        {
          "city": "Philadelphia",
          "state": "Pennsylvania"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT06051448"
    },
    {
      "nct_id": "NCT00343577",
      "title": "Antiproteinuric Agents and Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Fabry Disease",
        "Proteinuria"
      ],
      "interventions": [],
      "intervention_types": [],
      "sponsor": "University of Alabama at Birmingham",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "14 Years",
        "maximum_age": "95 Years",
        "sex": "ALL",
        "summary": "14 Years to 95 Years"
      },
      "enrollment_count": 12,
      "start_date": "2001-01",
      "completion_date": "2006-12",
      "has_results": false,
      "last_update_posted_date": "2013-11-19",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 1,
      "location_summary": "Birmingham, Alabama",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00343577"
    },
    {
      "nct_id": "NCT00097890",
      "title": "Replagal Enzyme Replacement Therapy for Adults With Fabry Disease",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE4"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "Replagal (Agalsidase Alfa)",
          "type": "DRUG"
        },
        {
          "name": "Replagal",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "National Institute of Neurological Disorders and Stroke (NINDS)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": null,
        "sex": "MALE",
        "summary": "Male only"
      },
      "enrollment_count": 25,
      "start_date": "2004-11",
      "completion_date": "2005-12",
      "has_results": false,
      "last_update_posted_date": "2008-03-04",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 1,
      "location_summary": "Bethesda, Maryland",
      "locations": [
        {
          "city": "Bethesda",
          "state": "Maryland"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00097890"
    },
    {
      "nct_id": "NCT04046224",
      "title": "Dose-Ranging Study of ST-920, an AAV2/6 Human Alpha Galactosidase A Gene Therapy in Subjects With Fabry Disease (STAAR)",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Fabry Disease"
      ],
      "interventions": [
        {
          "name": "ST-920",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Sangamo Therapeutics",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 36,
      "start_date": "2019-07-23",
      "completion_date": "2025-04-10",
      "has_results": true,
      "last_update_posted_date": "2026-04-14",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 9,
      "location_summary": "Irvine, California • Tampa, Florida • Atlanta, Georgia + 6 more",
      "locations": [
        {
          "city": "Irvine",
          "state": "California"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        },
        {
          "city": "Atlanta",
          "state": "Georgia"
        },
        {
          "city": "Chicago",
          "state": "Illinois"
        },
        {
          "city": "Iowa City",
          "state": "Iowa"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT04046224"
    },
    {
      "nct_id": "NCT03434262",
      "title": "SJDAWN: St. Jude Children's Research Hospital Phase 1 Study Evaluating Molecularly-Driven Doublet Therapies for Children and Young Adults With Recurrent Brain Tumors",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Anaplastic Astrocytoma",
        "Anaplastic Ependymoma",
        "Anaplastic Ganglioglioma",
        "Anaplastic Meningioma",
        "Anaplastic Oligodendroglioma",
        "Pleomorphic Xanthoastrocytoma, Anaplastic",
        "Atypical Teratoid/Rhabdoid Tumor",
        "Brain Cancer",
        "Brain Tumor",
        "Central Nervous System Neoplasms",
        "Choroid Plexus Carcinoma",
        "CNS Embryonal Tumor With Rhabdoid Features",
        "Ganglioneuroblastoma of Central Nervous System",
        "CNS Tumor",
        "Embryonal Tumor of CNS",
        "Ependymoma",
        "Glioblastoma",
        "Glioma",
        "Glioma, Malignant",
        "Medulloblastoma",
        "Medulloblastoma; Unspecified Site",
        "Medulloepithelioma",
        "Neuroepithelial Tumor",
        "Neoplasms",
        "Neoplasms, Neuroepithelial",
        "Papillary Tumor of the Pineal Region (High-grade Only)",
        "Pediatric Brain Tumor",
        "Pineal Parenchymal Tumor of Intermediate Differentiation (High-grade Only)",
        "Pineoblastoma",
        "Primitive Neuroectodermal Tumor",
        "Recurrent Medulloblastoma",
        "Refractory Brain Tumor",
        "Neuroblastoma. CNS",
        "Glioblastoma, IDH-mutant",
        "Glioblastoma, IDH-wildtype",
        "Medulloblastoma, Group 3",
        "Medulloblastoma, Group 4",
        "Glioma, High Grade",
        "Neuroepithelial Tumor, High Grade",
        "Medulloblastoma, SHH-activated and TP53 Mutant",
        "Medulloblastoma, SHH-activated and TP53 Wildtype",
        "Medulloblastoma, Chromosome 9q Loss",
        "Medulloblastoma, Non-WNT Non-SHH, NOS",
        "Medulloblastoma, Non-WNT/Non-SHH",
        "Medulloblastoma, PTCH1 Mutation",
        "Medulloblastoma, WNT-activated",
        "Ependymoma, Recurrent",
        "Glioma, Recurrent High Grade",
        "Glioma, Recurrent Malignant",
        "Embryonal Tumor, NOS",
        "Glioma, Diffuse Midline, H3K27M-mutant",
        "Embryonal Tumor With Multilayered Rosettes (ETMR)",
        "Ependymoma, NOS, WHO Grade III",
        "Ependymoma, NOS, WHO Grade II",
        "Medulloblastoma, G3/G4",
        "Ependymoma, RELA Fusion Positive"
      ],
      "interventions": [
        {
          "name": "Gemcitabine",
          "type": "DRUG"
        },
        {
          "name": "ribociclib",
          "type": "DRUG"
        },
        {
          "name": "sonidegib",
          "type": "DRUG"
        },
        {
          "name": "trametinib",
          "type": "DRUG"
        },
        {
          "name": "filgrastim",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "DRUG",
        "BIOLOGICAL"
      ],
      "sponsor": "St. Jude Children's Research Hospital",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "1 Year",
        "maximum_age": "39 Years",
        "sex": "ALL",
        "summary": "1 Year to 39 Years"
      },
      "enrollment_count": 68,
      "start_date": "2018-03-05",
      "completion_date": "2024-05-24",
      "has_results": false,
      "last_update_posted_date": "2024-05-31",
      "last_synced_at": "2026-10-21T18:41:18.127Z",
      "location_count": 1,
      "location_summary": "Memphis, Tennessee",
      "locations": [
        {
          "city": "Memphis",
          "state": "Tennessee"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT03434262"
    }
  ]
}